Prevalence of <i>BRCA1/2</i> germline mutations in 21 401 families with breast and ovarian cancer

Abstract

Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing.